Donanemab - Wikipedia
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Donanemab: Uses, Interactions, Mechanism of Action - DrugBank …
2021年3月21日 · Donanemab is a monoclonal antibody targeted against the insoluble, modified, N-terminal truncated form of the β-amyloid present only in brain amyloid plaques called pyroglutamate amyloid beta (Aβ). 1,2 Upon binding to pyroglutamate Aβ at position 3 (pGlu3-Aβ, AβpE3), 4 donanemab promotes plaque removal through microglial-mediated ...
KISUNLA is supplied in single-dose vials available in a concentration of 350 mg/20 mL (17.5 mg/mL). Each mL of solution contains 17.5 mg donanemab-azbt, anhydrous citric acid (0.32 mg),...
Donanemab - ALZFORUM
2019年2月14日 · Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug recognizes Aβ (p3-42), a pyroglutamate form of Aβ that is aggregated in amyloid plaques. Most Aβ antibodies in therapeutic development bind various soluble or insoluble species but have low affinity to deposited amyloid plaques.
Donanemab - LiverTox - NCBI Bookshelf - National Center for ...
2024年10月4日 · Donanemab is a humanized monoclonal antibody to aggregated amyloid β which has been approved for use in Alzheimer disease with mild cognitive impairment or mild dementia. Donanemab is associated with a minimal rate of serum aminotransferase elevations during therapy and has not been linked to instances of clinically apparent liver injury.
Donanemab for Alzheimer’s Disease: A Systematic Review of …
Donanemab is a humanized antibody and acts against the N-truncated pyroglutamate amyloid-β peptide at position 3 (pGlu3-Aβ, AβpE3) and is currently being investigated as a treatment for AD [15].
RCSB PDB - 7CM0: Crystal structure of a glutaminyl cyclase in …
2020年7月23日 · The crystal structure of human QC (hQC) in complex with 214 indicated tight binding at the active site, supporting that the specific inhibition of QC results in potent in vitro and in vivo activity. Considering the recent clinical success of donanemab, which targets Aβ Ν3pE , small molecule-based QC inhibitors may also provide potential ...
Donanemab in Early Symptomatic Alzheimer Disease - PubMed …
Donanemab is an immunoglobulin G1 monoclonal antibody directed against insoluble, modified, N-terminal truncated form of β-amyloid present only in brain amyloid plaques.
Donanemab Population Pharmacokinetics, Amyloid Plaque …
2023年2月18日 · Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER-ALZ study (NCT03367403). The objectives of the current analyses are to characterize (i) the population pharmacokinetics of donanemab, (ii) the relationship ...
Donanemab: Uses, Side Effects, Dosage, Warnings - Drugs.com
Last updated on Jul 3, 2024. What is donanemab? Donanemab (Kisunla) is used to Alzheimer’s disease to help slow down the decline in memory, thinking, and daily functioning. This means that Alzheimer’s disease does not progress as quickly, and people can continue living their lives doing their daily activities and hobbies for a longer time.